Drug Development Too Risky Without Pharmacogenomics, McClellan Says
The future of drug development is too risky without the use of pharmacogenomics-based therapies, FDA Commissioner McClellan told a Drug Information Association workshop Nov. 13
The future of drug development is too risky without the use of pharmacogenomics-based therapies, FDA Commissioner McClellan told a Drug Information Association workshop Nov. 13